Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
01:15pm, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
AUSTIN, Texas, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against c
Trading Ideas On The Upcoming CTAD 2022 Conference
03:27pm, Wednesday, 02'nd Nov 2022
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie
Why Is Cassava Sciences (SAVA) Stock Down 10% Today?
02:59pm, Wednesday, 02'nd Nov 2022
Shares of Cassava Sciences (NASDAQ: SAVA ) declined by as much as 12% today but have since recovered to the $35 range, down about 4%. This was most likely attributed to the release of an article by Pr
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
06:21pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
03:48pm, Tuesday, 01'st Nov 2022
Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
09:50pm, Monday, 31'st Oct 2022 Zacks Investment Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $36.44, moving -0.87% from the previous trading session.
Cassava Sciences Announces Expansion of Leadership Team
01:15pm, Thursday, 27'th Oct 2022 GlobeNewswire Inc.
AUSTIN, Texas, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced the expansion of its leader
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
09:50pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $34.31, moving +0.7% from the previous trading session.
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
08:02pm, Friday, 21'st Oct 2022
Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
09:50pm, Monday, 17'th Oct 2022 Zacks Investment Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $35.92, moving -1.48% from the previous trading session.
Cassava Sciences Announces Initiation of an Open-label Extension Study
01:15pm, Thursday, 13'th Oct 2022 GlobeNewswire Inc.
AUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an
SAVA Stock Alert: Cassava Sciences Extends Trial
12:23pm, Thursday, 13'th Oct 2022
Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in focus after the company announced that it would begin an open-label study on its investigational Alzheimer's disease ( AD ) drug, simufilam. The
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
10:00pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
Cassava Sciences, Inc. (SAVA) closed at $35.64 in the latest trading session, marking a -1.87% move from the prior day.
3 Alzheimer Stocks To Buy As The Race For A Cure Heats Up
09:29am, Friday, 07'th Oct 2022 Investing.com
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
04:41pm, Thursday, 06'th Oct 2022 Benzinga
Gainers
Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of Radia
